In:
Journal of Cellular Biochemistry, Wiley, Vol. 111, No. 3 ( 2010-10-15), p. 564-573
Kurzfassung:
Myostatin is a negative regulator of skeletal muscle mass. The pathways employed in modulating myostatin gene expression are scarcely known. We aimed to determine the signaling pathway of myostatin induction by a histone deacetylase (HDAC) inhibitor–trichostatin A (TSA) in differentiated C 2 C 12 myocytes. TSA increased myostatin mRNA expression up to 40‐fold after treatment for 24 h, and induced myostatin promoter activity up to 3.8‐fold. Pretreatment with actinomycin D reduced the TSA‐induced myostatin mRNA by 93%, suggesting TSA‐induced myostatin expression mainly at the transcriptional level. Pretreatment with p38 MAPK (SB203580) and JNK (SP600125) inhibitors, but not ERK (PD98059) inhibitor, blocked TSA‐induced myostatin expression, respectively, by 72% and 43%. Knockdown of p38 MAPK by RNAi inhibited the TSA‐induced myostatin expression by 77% in C 2 C 12 myoblasts. The protein levels of phosphorylated p38 MAPK, JNK, but not ERK, increased with TSA treatment in differentiated C 2 C 12 cells. Direct activation of p38 MAPK and JNK by anisomycin in the absence of TSA increased myostatin mRNA by fourfold. The phosphorylated form of the kinase MKK3/4/6 and ASK1, upstream cascades of p38 MAPK and JNK, also increased with TSA treatment. We concluded that the induction of myostatin by TSA treatment in differentiated C 2 C 12 cells is in part through ASK1‐MKK3/6‐p38 MAPK and ASK1‐MKK4‐JNK signaling pathways. Activation of p38 MAPK and JNK axis is necessary, but not sufficient for TSA‐induced myostatin expression. J. Cell. Biochem. 111: 564–573, 2010. © 2010 Wiley‐Liss, Inc.
Materialart:
Online-Ressource
ISSN:
0730-2312
,
1097-4644
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2010
ZDB Id:
1479976-5
SSG:
12
